Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Neoplasms, Plasma Cell 1NSCLC 1Multiple Myeloma 1Leukemia, Myeloid, Chronic-Phase 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Magnetic Resonance Spectroscopy 9pembrolizumab 7Specimen Handling 7Biopsy 7Leucovorin 5Gemcitabine 5Cisplatin 5durvalumab 4Oxaliplatin 4Fluorouracil 4Capecitabine 4Paclitaxel 3Nivolumab 3Irinotecan 3Carboplatin 3tislelizumab 2olaparib 2fludarabine 2atezolizumab 2Trastuzumab 2Taxes 2Radiation Dose Hypofractionation 2Radiation 2Ipilimumab 2Fluorodeoxyglucose F18 2Cyclophosphamide 2zimberelimab 1varlilumab 1tucatinib 1tremelimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Cholangiocarcinoma × Pharmaceutical Preparations × Clear all
NCT04238637 2025-12-05

Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Active not recruiting
50 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡